Evidence Supporting the Safety of Pegylated Diethylaminoethyl-Chitosan Polymer as a Nanovector for Gene Therapy Applications

References

• Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387. doi:10.1007/s11095-016-1958-527299311
   PubMed Web of Science ®Google Scholar
• Shi Q, Rondon-Cavanzo E-P, Dalla Picola IP, et al. In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice. Int J Nanomed. 2018;13:387–402. doi:10.2147/IJN.S146942
   PubMed Web of Science ®Google Scholar
• Shi Q, Tiera MJ, Zhang X, Dai K, Benderdour M, Fernandes JC. Chitosan-DNA/siRNA nanoparticles for gene therapy IntechOpen Limited ed. London, UK. In: Yuan X, editor. Non-Viral Gene Therapy. 19 2011:455–480
   Google Scholar
• Muxika A, Etxabide A, Uranga J, Guerrero P, De La Caba K. Chitosan as a bioactive polymer: processing, properties and applications. Int J Biol Macromol. 2017;105:1358–1368. doi:10.1016/j.ijbiomac.2017.07.08728735006
   PubMed Web of Science ®Google Scholar
• Abdelhamid HN, El-Bery HM, Metwally AA, Elshazly M, Hathout RM. Synthesis of CdS-modified chitosan quantum dots for the drug delivery of Sesamol. Carbohydr Polym. 2019;214:90–99. doi:10.1016/j.carbpol.2019.03.02430926012
   PubMed Web of Science ®Google Scholar
• Zhao D, Yu S, Sun B, Gao S, Guo S, Zhao K. Biomedical applications of chitosan and its derivative nanoparticles. Polymers. 2018;10(4):462. doi:10.3390/polym10040462
   PubMed Web of Science ®Google Scholar
• Mohebbi S, Nezhad MN, Zarrintaj P, et al. Chitosan in biomedical engineering: a critical review. Curr Stem Cell Res Ther. 2019;14(2):93–116. doi:10.2174/1574888X1366618091214202830207244
   PubMed Web of Science ®Google Scholar
• Dowaidar M, Nasser Abdelhamid H, Hällbrink M, Langel Ü, Zou X. Chitosan enhances gene delivery of oligonucleotide complexes with magnetic nanoparticles–cell-penetrating peptide. J Biomater Appl. 2018;33(3):392–401. doi:10.1177/088532821879662330223733
   PubMed Web of Science ®Google Scholar
• Guo X, Sun T, Zhong R, et al. Effects of chitosan oligosaccharides on human blood components. Front Pharmacol. 2018;9:1412. doi:10.3389/fphar.2018.0141230559672
   PubMed Web of Science ®Google Scholar
• Dash BC, Réthoré G, Monaghan M, Fitzgerald K, Gallagher W, Pandit A. The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility. Biomaterials. 2010;31(32):8188–8197. doi:10.1016/j.biomaterials.2010.07.06720701967
   PubMed Web of Science ®Google Scholar
• Shelma R, Sharma CP. Development of lauroyl sulfated chitosan for enhancing hemocompatibility of chitosan. Colloids Surf B Biointerfaces. 2011;84(2):561–570. doi:10.1016/j.colsurfb.2011.02.01821367586
   PubMed Web of Science ®Google Scholar
• Mohammadi F, Golafshan N, Kharaziha M, Ashrafi A. Chitosan-heparin nanoparticle coating on anodized NiTi for improvement of blood compatibility and biocompatibility. Int J Biol Macromol. 2019;127:159–168. doi:10.1016/j.ijbiomac.2019.01.02630629994
   PubMed Web of Science ®Google Scholar
• Pereira P, Pedrosa SS, Correia A, et al. Biocompatibility of a self-assembled glycol chitosan nanogel. Toxicol in Vitro. 2015;29(3):638–646. doi:10.1016/j.tiv.2014.11.00425482991
   PubMed Web of Science ®Google Scholar
• Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna T, Pessoa JA. Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci. 2007;10(3):388–404.17727802
   PubMed Web of Science ®Google Scholar
• Halamoda‐Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer‐Hoffmann S. Mapping of the available standards against the regulatory needs for nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(1):e1531. doi:10.1002/wnan.153129923692
   PubMed Web of Science ®Google Scholar
• Urbán P, Liptrott NJ, Bremer S. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(3):e1546. doi:10.1002/wnan.154630556649
   PubMed Web of Science ®Google Scholar
• ISO/TR 16197:2014(E). Nanotechnologies compilation and description of toxicological screening methods for manufactured nanomaterials. Available from: www.iso.org. Accessed 724, 2020.
   Google Scholar
• Locascio L, Reipa V, Zook J, Pleus R. Nanomaterial toxicity: emerging standards and efforts to support standards development In: Murashov V, Howard J, editors. Nanotechnology Standards. Springer Science & Business Media; 2011:179–208.
   Google Scholar
• de Souza RHFV, Dalla Picola IP, Shi Q, et al. Diethylaminoethyl-chitosan as an efficient carrier for siRNA delivery: improving the condensation process and the nanoparticles properties. Int J Biol Macromol. 2018;119:186–197. doi:10.1016/j.ijbiomac.2018.07.07230031084
   PubMed Web of Science ®Google Scholar
• EN ISO 10993–4:2009. Biological evaluation of medical devices part 4: selection of tests for interactions with blood. Available from: www.iso.org. Accessed 724, 2020.
   Google Scholar
• ASTM F1903–10. Standard practice for testing for biological responses to particles in vitro. West Conshohocken, PA:ASTM International; 2010 DOI: 10.1520/F1903-10.
   Google Scholar
• American Society for Testing and Materials [homepage on the Internet]. E56.03 environment, health, and safety. Available from: https://www.astm.org/COMMIT/SUBCOMMIT/E5603.htm. Accessed 120, 2018.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Assay cascade protocols. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Abrams MT, Koser ML, Seitzer J, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2010;18(1):171–180. doi:10.1038/mt.2009.20819738601
   PubMed Web of Science ®Google Scholar
• Seitzer J, Zhang H, Koser M, Pei Y, Abrams M. Effect of biological matrix and sample preparation on qPCR quantitation of siRNA drugs in animal tissues. J Pharmacol Toxicol Methods. 2011;63(2):168–173. doi:10.1016/j.vascn.2010.09.00520884364
   PubMed Web of Science ®Google Scholar
• Oliveira F, Dalla Picola IP, Shi Q, et al. Synthesis and evaluation of diethylethylamine–chitosan for gene delivery: composition effects on the in vitro transfection efficiency. Nanotechnology. 2013;24(5):055101. doi:10.1088/0957-4484/24/5/05510123306549
   PubMed Web of Science ®Google Scholar
• Cho KC, Jeong JH, Chung HJ, Joe CO, Kim SW, Park TG. Folate receptor-mediated intracellular delivery of recombinant caspase-3 for inducing apoptosis. J Control Release. 2005;108(1):121–131. doi:10.1016/j.jconrel.2005.07.01516139916
   PubMed Web of Science ®Google Scholar
• Fernandes JC, Qiu X, Winnik FM, et al. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies. Int J Nanomed. 2012;7:5833–5845. doi:10.2147/IJN.S35567
   PubMed Web of Science ®Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Neun BW, Ilinskaya AN, Dobrovolskaia MA. NCL method STE-1.1 detection and quantification of gram negative bacterial endotoxin contamination in nanoparticle formulations by end point chromogenic LAL assay. Version 1.3. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018..
   Google Scholar
• Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release. 2013;172(2):456–466. doi:10.1016/j.jconrel.2013.05.02523742883
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration [homepage on the Internet]. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. Accessed 120, 2019.
   Google Scholar
• ASTM E2526-08(2013), Standard Test Method for Evaluation of Cytotoxicity of Nanoparticulate Materials in Porcine Kidney Cells and Human Hepatocarcinoma Cells. West Conshohocken, PA:ASTM International;2013. doi:10.1520/E2526-08R13.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Stern ST, Adiseshaiah PP, Potter TM. NCL method GTA-2 hep G2 hepatocarcinoma cytotoxicity assay. Version 1.2. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Potter TM, Neun BW, Rodriguez J, Ilinskaya AN, Dobrovolskaia MA. NCL method ITA-10 preparation of human whole blood and peripheral blood mononuclear cell cultures to analyze nanoparticle potential to induce inflammatory cytokines, chemokines and interferons in vitro. Version 1.2. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• EN ISO 10993-5:2009. Biological evaluation of medical devices - Part 5: tests for in vitro cytotoxicity. Available from: www.iso.org. Accessed 724, 2020.
   Google Scholar
• ASTM E2524-08(2013). Standard test method for analysis of hemolytic properties of nanoparticles. West Conshohocken, PA:ASTM International; 2013. doi:10.1520/E2524-08R13.
   Google Scholar
• Banerjee N, Sengupta S, Roy A, Ghosh P, Das K, Das S. Functional alteration of a dimeric insecticidal lectin to a monomeric antifungal protein correlated to its oligomeric status. PLoS One. 2011;6(4):e18593. doi:10.1371/journal.pone.001859321490929
   PubMed Web of Science ®Google Scholar
• Lima J, Sarmento RR, Souza J, et al. Evaluation of hemagglutination activity of chitosan nanoparticles using human erythrocytes. Biomed Res Int. 2015;2015.
   Web of Science ®Google Scholar
• Stavitsky AB, Jarchow C. Micromethods for the study of proteins and antibodies: I. Procedure and general applications of hemagglutination and hemagglutination-inhibition reactions with tannic acid and protein-treated red blood cells. J Immunol. 1954;72(5):360–367.13163409
   PubMed Web of Science ®Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Neun BW, Ilinskaya AN, Dobrovolskaia MA. NCL method ITA-5.1 qualitative analysis of total complement activation by western blot. Version 1.2. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Rodriguez J, Neun BW, Ilinskaya AN, Dobrovolskaia MA. NCL method ITA-2.2 analysis of platelet aggregation by light transmission aggregometry. Version 1.2. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Rodriguez J, Neun BW, Ilinskaya AN, Dobrovolskaia MA. NCL method ITA-2.1 analysis of platelet aggregation by cell counting. Version 1.2. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Rodriguez J, Neun BW, Ilinskaya AN, Dobrovolskaia MA. NCL method ITA-12 analysis of nanoparticle effects on plasma coagulation times in vitro. Version 1.2. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Rodriguez J, Neun BW, Ilinskaya AN, Dobrovolskaia MA. NCL method ITA-7 detection of nitric oxide production by the macrophage cell line RAW264.7. Version 1.2. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Stern ST, Zolnik BS. NCL method GTA-7 hepatocyte primary ROS assay. Version 1.1. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Ginzburg AL, Truong L, Tanguay RL, Hutchison JE. Synergistic toxicity produced by mixtures of biocompatible gold nanoparticles and widely used surfactants. ACS Nano. 2018;12(6):5312–5322. doi:10.1021/acsnano.8b0003629697962
   PubMed Web of Science ®Google Scholar
• Nadesh RND, P R S, Vadakumpully S, et al. Hematotoxicological analysis of surface-modified and -unmodified chitosan nanoparticles. J Biomed Mater Res A. 2013;101(10):2957–2966. doi:10.1002/jbm.a.3459123613460
   PubMed Web of Science ®Google Scholar
• International Organization for Standardization [homepage on the Internet]. ISO/TC 229 nanotechnologies. Available from: https://www.iso.org/committee/381983/x/catalogue/. Accessed 120, 2018.
   Google Scholar
• American Society for Testing and Materials [homepage on the Internet]. Nanotechnology standards. Available from: https://www.astm.org/Standards/nanotechnology-standards.html. Accessed 120, 2018.
   Google Scholar
• Shen J, Hilgenbrink AR, Xia W, et al. Folate receptor‐β constitutes a marker for human proinflammatory monocytes. J Leukoc Biol. 2014;96(4):563–570. doi:10.1189/jlb.2AB0713-372R25015955
   PubMed Web of Science ®Google Scholar
• Yang C, Gao S, Kjems J. Folic acid conjugated chitosan for targeted delivery of siRNA to activated macrophages in vitro and in vivo. J Mater Chem B. 2014;2(48):8608–8615. doi:10.1039/C4TB01374C32262219
   PubMed Web of Science ®Google Scholar
• Wang X, Yao S, Ahn H-Y, et al. Folate receptor targeting silica nanoparticle probe for two-photon fluorescence bioimaging. Biomed Opt Express. 2010;1(2):453–462. doi:10.1364/BOE.1.00045321258480
   PubMed Web of Science ®Google Scholar
• Contini C, Schneemilch M, Gaisford S, Quirke N. Nanoparticle–membrane interactions. J Exp Nanosci. 2018;13(1):62–81. doi:10.1080/17458080.2017.1413253
   Web of Science ®Google Scholar
• Lin J, Alexander-Katz A. Cell membranes open “doors” for cationic nanoparticles/biomolecules: insights into uptake kinetics. ACS Nano. 2013;7(12):10799–10808. doi:10.1021/nn404055324251827
   PubMed Web of Science ®Google Scholar
• Leroueil PR, Berry SA, Duthie K, et al. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett. 2008;8(2):420–424. doi:10.1021/nl072292918217783
   PubMed Web of Science ®Google Scholar
• Hong S, Leroueil PR, Janus EK, et al. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem. 2006;17(3):728–734. doi:10.1021/bc060077y16704211
   PubMed Web of Science ®Google Scholar
• Jiang H-L, Kim Y-K, Arote R, et al. Mannosylated chitosan-graft-polyethylenimine as a gene carrier for raw 264.7 cell targeting. Int J Pharm. 2009;375(12):133–139. doi:10.1016/j.ijpharm.2009.03.03319481699
   PubMedGoogle Scholar
• Xiao B, Ma P, Ma L, et al. Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. J Colloid Interface Sci. 2017;490:520–528. doi:10.1016/j.jcis.2016.11.08827918990
   PubMed Web of Science ®Google Scholar
• Yang Y, Xing R, Liu S, et al. Immunostimulatory effects of sulfated chitosans on RAW 264.7 mouse macrophages via the activation of PI3 K/Akt signaling pathway. Int J Biol Macromol. 2018;108:1310–1321. doi:10.1016/j.ijbiomac.2017.11.04229129634
   PubMed Web of Science ®Google Scholar
• Martínez-Torres AC, Zarate-Triviño DG, Lorenzo-Anota HY, Ávila-Ávila A, Rodríguez-Abrego C, Rodríguez-Padilla C. Chitosan gold nanoparticles induce cell death in HeLa and MCF-7 cells through reactive oxygen species production. Int J Nanomed. 2018;13:3235–3250. doi:10.2147/IJN.S165289
   PubMed Web of Science ®Google Scholar
• Alinejad V, Somi MH, Baradaran B, et al. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. Biomed Pharmacother. 2016;83:229–240. doi:10.1016/j.biopha.2016.06.03727372407
   PubMed Web of Science ®Google Scholar
• Balan V, Verestiuc L. Strategies to improve chitosan hemocompatibility: a review. Eur Polym J. 2014;53:171–188. doi:10.1016/j.eurpolymj.2014.01.033
   Web of Science ®Google Scholar
• Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487–495. doi:10.1021/mp800032f18510338
   PubMed Web of Science ®Google Scholar
• Fan W, Yan W, Xu Z, Ni H. Erythrocytes load of low molecular weight chitosan nanoparticles as a potential vascular drug delivery system. Colloids Surf B Biointerfaces. 2012;95:258–265. doi:10.1016/j.colsurfb.2012.03.00622469561
   PubMed Web of Science ®Google Scholar
• Nanotechnology Characterization Laboratory [homepage on the Internet]. Clogston JD. NCL method PCC-2 measuring zeta potential of nanoparticles. Version 1.1. Available from: https://ncl.cancer.gov/resources/assay-cascade-protocols. Accessed 120, 2018.
   Google Scholar
• Shankar E, Ramasubramanian A. Hemocompatibility of Nanoparticles In: Sitharaman B, editor. Nanobiomaterials handbook. CRC Press; 2016:1–31.
   Google Scholar
• Elsabahy M, Wooley KL. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev. 2013;42(12):5552–5576. doi:10.1039/c3cs60064e23549679
   PubMed Web of Science ®Google Scholar
• Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci. 1997;2(1):d12–d26. doi:10.2741/A1719159205
   PubMedGoogle Scholar
• O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–487. doi:10.1016/j.immuni.2008.03.00218400190
   PubMed Web of Science ®Google Scholar
• Bueter CL, Lee CK, Wang JP, Ostroff GR, Specht CA, Levitz SM. Spectrum and mechanisms of inflammasome activation by chitosan. J Immunol. 2014;192(12):5943–5951. doi:10.4049/jimmunol.130169524829412
   PubMed Web of Science ®Google Scholar
• Feng J, Zhao L, Yu Q. Receptor-mediated stimulatory effect of oligochitosan in macrophages. Biochem Biophys Res Commun. 2004;317(2):414–420. doi:10.1016/j.bbrc.2004.03.04815063774
   PubMed Web of Science ®Google Scholar
• Fong D, Hoemann CD. Chitosan immunomodulatory properties: perspectives on the impact of structural properties and dosage. Future Sci OA. 2017;4(1):FSO225. doi:10.4155/fsoa-2017-006429255618
   PubMed Web of Science ®Google Scholar
• Carroll EC, Jin L, Mori A, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity. 2016;44(3):597–608. doi:10.1016/j.immuni.2016.02.00426944200
   PubMed Web of Science ®Google Scholar
• Azuma K, Osaki T, Minami S, Okamoto Y. Anticancer and anti-inflammatory properties of chitin and chitosan oligosaccharides. J Funct Biomater. 2015;6(1):33–49. doi:10.3390/jfb601003325594943
   PubMed Web of Science ®Google Scholar
• Beyerle A, Irmler M, Beckers J, Kissel T, Stoeger T. Toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications. Mol Pharm. 2010;7(3):727–737. doi:10.1021/mp900278x20429563
   PubMedGoogle Scholar
• Manke A, Wang L, Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. Biomed Res Int. 2013;2013:942916. doi:10.1155/2013/94291624027766
   PubMed Web of Science ®Google Scholar
• Ngo D-H, Vo T-S, Ngo D-N, et al. Biological effects of chitosan and its derivatives. Food Hydrocoll. 2015;51:200–216. doi:10.1016/j.foodhyd.2015.05.023
   Web of Science ®Google Scholar
• Qiao Y, Bai X-F, Du Y-G. Chitosan oligosaccharides protect mice from LPS challenge by attenuation of inflammation and oxidative stress. Int Immunopharmacol. 2011;11(1):121–127. doi:10.1016/j.intimp.2010.10.01621059391
   PubMed Web of Science ®Google Scholar
• Bai R, Yong H, Zhang X, Liu J, Liu J. Structural characterization and protective effect of gallic acid grafted O-carboxymethyl chitosan against hydrogen peroxide-induced oxidative damage. Int J Biol Macromol. 2020;143:49–59. doi:10.1016/j.ijbiomac.2019.12.03731812751
   PubMed Web of Science ®Google Scholar
• Jesus S, Marques AP, Duarte A, et al. Chitosan nanoparticles: shedding light on immunotoxicity and hemocompatibility. Front Bioeng Biotechnol. 2020;8:100. doi:10.3389/fbioe.2020.0010032154232
   PubMed Web of Science ®Google Scholar
• Sarangapani S, Patil A, Ngeow YK, Elsa Mohan R, Asundi A, Lang MJ. Chitosan nanoparticles’ functionality as redox active drugs through cytotoxicity, radical scavenging and cellular behaviour. Integr Biol. 2018;10(5):313–324. doi:10.1039/C8IB00038G
   Google Scholar
• Xu Q, Liu M, Liu Q, Wang W, Du Y, Yin H. The inhibition of LPS-induced inflammation in RAW264. 7 macrophages via the PI3K/Akt pathway by highly N-acetylated chitooligosaccharide. Carbohydr Polym. 2017;174:1138–1143. doi:10.1016/j.carbpol.2017.07.05128821038
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration [homepage on the Internet]. Nanotechnology/nanotoxicology; 2019 Available from: https://www.fda.gov/medical-devices/cdrh-research-programs/nanotechnologynanotoxicology. Accessed 1010, 2019.
   Google Scholar
• Food and Drug Administration [homepage on the Internet]. Nanotechnology task force report; 2007 Available from: https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-task-force-report-2007#definitions. Accessed 120, 2019.
   Google Scholar
• ISO/TR 10993–22:2017. Biological evaluation of medical devices part 22: guidance on nanomaterials. Available from: www.iso.org. Accessed 724, 2020.
   Google Scholar